Nance-Horan syndrome
UK Proposes Raising Payment Scheme for Branded Medicines to Nearly 25% Amid Industry Pushback
UK medicine pricing; NHS spending; statutory scheme; drugmakers; payment percentage; pharmaceutical rebates; industry response; consultation 2025
Bristol Myers Squibb to Launch Schizophrenia Drug Cobenfy in UK at US Price
Bristol Myers Squibb; Cobenfy; schizophrenia; UK launch; drug pricing; US list price; NHS; cholinergic receptors; antipsychotic; 2026
A Concerning Pattern: Pharma Mulls UK Divestments as Government Action Lags in Life Sciences
UK life sciences; pharmaceutical divestment; Merck; AstraZeneca; Sanofi; Eli Lilly; R&D investment; drug pricing; government policy; NHS drug spending
Eli Lilly Pauses UK Biotech Incubator Plans Amid Concerns Over NHS Drug Pricing
Eli Lilly; Gateway Labs; UK biotech incubator; pause; investment; NHS drug spending; life sciences; biotech industry; government funding; pharmaceutical innovation
UK Pharma Trade Group Calls for Overhaul of Government’s Life Sciences Investment Evaluation and Medicines Pricing Schemes
UK life sciences; ABPI; VPAG; pharma trade group; investment evaluation; medicines pricing; government review; NHS; innovation; statutory scheme
GSK Launches Groundbreaking Study on Shingrix and Dementia Risk Reduction
GSK, Shingrix, dementia, UK Dementia Research Institute, Health Data Research UK, NHS data, real-world experiment
NHS England Approves Groundbreaking CRISPR Gene Therapy for Sickle Cell Disease
Casgevy, exagamglogene autotemcel, CRISPR gene therapy, sickle cell disease, NHS England, Vertex Pharmaceuticals, NICE approval
Limited Access to Mounjaro: England’s NHS Rolls Out Obesity Drug with Phased Approach
Mounjaro, obesity drug, NHS England, limited access, phased rollout, weight loss medication, tirzepatide.
NICE Rejects Enhertu for NHS Use Due to Pricing Stalemate with AstraZeneca and Daiichi Sankyo
Enhertu, NICE, AstraZeneca, Daiichi Sankyo, breast cancer, pricing stalemate, NHS, England
NICE Rejects Alzheimer’s Drug Kisunla Despite UK Regulatory Approval
NICE, Alzheimer’s disease, donanemab, Kisunla, Eli Lilly, MHRA, NHS, cost-effectiveness